Answers are grounded in this paper and cite their sources.
Expert opinion highlights therapeutic sequencing challenges in multiple myeloma, suggesting a need for refined clinical guidance.
multiple myeloma, combination therapy, triplet regimen, doublet regimen, sequencing strategyOverall survival (OS) and health related quality of life (QoL) are the two important patient-centered endpoints in oncology.Historically in oncology, improvements in surrogates such as progression-free survival (PFS) or response rate have not been sufficient to prove superiority of combination over sequential therapy, when these benefits do not translate to improved OS or QoL.For instance, a 2003 phase III clinical trial comparing the combination of doxorubicin and paclitaxel vs. single agent doxorubicin or paclitaxel for metastatic breast cancer showed that combination therapy yielded superior overall response rates and longer time to treatment failure.(Sledge et al., 2003) Despite these benefits, the study authors rejected combination therapy on the basis of its failure to improve OS or QoL.Instead, the authors preferred single agent sequential therapy.The same logic has not been applied to multiple myeloma.Multiple pivotal phase 3 clinical trials evaluating combination vs sequential therapy use primary endpoints of PFS.This raises several concerns.First, the validity of PFS as a surrogate for OS is questionable.In a recent analysis of 21 RCTs on newly diagnosed MM, the correlation (R 2 ) between PFS and OS was found to be just 0.65, which is "weak" according to standards published by the independent German Institute for Quality and Efficiency in Healthcare and suggests that improvements in PFS may not predict OS benefit.(Cliff and Rehman Mohyuddin, 2022;Etekal et al., 2023) While some MM RCTs such as SWOG
No takes yet. Share an insight, caveat, or question.
Walia et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: